Navigation

2005/018 NICE extends its recommendations for the use of drugs for the treatment of advanced colorectal cancer

The National Institute for Health and Care Excellence (NICE) has today issued updated guidance to the NHS in England and Wales on the use of three drugs for people with advanced colorectal cancer. The guidance, based on a review of the latest evidence, extends the recommendations for the use of irinotecan and oxaliplatin from NICE's original guidance (no.33, March 2002) to include their use as first line therapy for all people with the disease. A third drug, raltitrexed, remains not recommended and its use is limited to studies.

This page was last updated: 03 August 2007

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.

Selected, reliable information for health and social care in one place

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.